Comparison · NCT00348348-9c8f8f4e
Moxifloxacin Solution vs Besifloxacin Suspension: Microbial Eradication
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Moxifloxacin Solution vs Besifloxacin Suspension: Microbial Eradication. Trial comparisons, record NCT00348348-9c8f8f4e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00348348-9c8f8f4e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.847 | 0.8 | 0.884 | wilson | |
| Risk in group 2 | 0.873 | 0.826 | 0.909 | wilson | |
| Risk difference, group 1 minus group 2 | -0.026 | -0.0848 | 0.0338 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.97 | 0.906 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.805 | 0.492 | 1.32 | log | |
| Number needed to treat, for one fewer participant with the outcome on Moxifloxacin Solution than on Besifloxacin Suspension | 38.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Moxifloxacin Solution | Moxifloxacin hydrochloride ophthalmic solution 0.5% | 238 | 281 | OG000 |
| Group 2 | Besifloxacin Suspension | Besifloxacin ophthalmic suspension 0.6% | 220 | 252 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Microbial Eradication
- Description
- Microbial eradication of baseline bacterial infection. modified intent to treat (mITT), culture confirmed, as treated
- Time frame
- Day 8 or Day 9
- Population
- modified intent to treat (mITT), culture confirmed, as treated
Source ClinicalTrials.gov
Trial
- Title
- A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis
- NCT number
- NCT00348348
- Phases
- PHASE3
- Conditions
- Acute Bacterial Conjunctivitis
- Interventions
- Besifloxacin, Moxifloxacin solution
- Lead sponsor
- Bausch & Lomb Incorporated
- Results first posted
- 2009-08-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00348348?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00348348-9c8f8f4e